Orthofix Medical (NASDAQ:OFIX) Stock: Insider Juniper Investment Company, Ll Buys 675,000 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Juniper Investment Company, Ll acquired 675,000 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was bought at an average cost of $7.41 per share, with a total value of $5,001,750.00. Following the acquisition, the insider owned 4,446,216 shares in the company, valued at $32,946,460.56. The trade was a 17.90% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Juniper Investment Company, Ll also recently made the following trade(s):

• On Wednesday, November 11th, Juniper Investment Company, Ll bought 14,803 shares of Orthofix Medical stock. The stock was purchased at an average cost of $7.04 per share, with a total value of $104,213.12.

Orthofix Medical Stock Down 3.3%

OFIX traded down $0.24 during trading on Thursday, reaching $6.94. 560,217 shares of the stock were exchanged, compared to its average volume of 375,534. The stock has a market cap of $282.69 million, a P/E ratio of -6.20 and a beta of 0.66. Orthofix Medical Inc. has a twelve month low of $6.52 and a twelve month high of $16.42. The stock’s 50 day moving average price is $9.16 and its two-hundred day moving average price is $10.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.67 and a current ratio of 3.11.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, November 9th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $207.86 million for the quarter, compared to analyst estimates of $210.52 million. Orthofix Medical had a negative net margin of 5.39% and a negative return on equity of 10.32%. Equities analysts expect that Orthofix Medical Inc. will post -1.29 EPS for the current year.

Institutional Investors Weigh In On Orthofix Medical

Several hedge funds have recently added to or reduced their stakes in the business. Boston Partners raised its position in shares of Orthofix Medical by 39.8% in the third quarter. Boston Partners now owns 36,989 shares of the medical device company’s stock valued at $348,000 after purchasing an additional 10,535 shares during the period. Voya Investment Management LLC lifted its stake in shares of Orthofix Medical by 69.7% during the 3rd quarter. Voya Investment Management LLC now owns 197,930 shares of the medical device company’s stock worth $1,863,000 after buying an additional 81,298 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Orthofix Medical by 37.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 274,157 shares of the medical device company’s stock worth $2,580,000 after buying an additional 74,838 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Orthofix Medical by 2,434.1% during the 3rd quarter. Parallel Advisors LLC now owns 3,269 shares of the medical device company’s stock worth $31,000 after buying an additional 3,140 shares during the period. Finally, CenterBook Partners LP acquired a new position in Orthofix Medical in the 3rd quarter valued at about $320,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on OFIX. TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a research note on Tuesday. Weiss Ratings downgraded Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Finally, Canaccord Genuity Group dropped their price objective on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.75.

Orthofix Medical Company Profile

Orthofix Medical Inc. develops and markets medical technologies for spine and orthopedic care. Its products include spinal implants and biologics, bone growth stimulation systems, and solutions used in fracture treatment and limb reconstruction. The company serves hospitals, surgeons, and other health care providers through its Orthofix and SeaSpine businesses. Its offerings span surgical products as well as noninvasive and specialized orthopedic treatments. Orthofix and SeaSpine completed a merger in 2023, combining their spine and orthopedic product portfolios.